Clinical Trials Logo
  1. Home
  2. Hepatitis B Virus
  3. NCT04046107

Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy

Hepatitis B Virus Clinical Trial

Official title:
Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy: A Phase I/II Ascending Multiple Dose Study

Clinical Trial Summary

The purpose of this study is to evaluate the safety and immunotherapeutic activity of cemiplimab in participants with hepatitis B virus (HBV) on suppressive antiviral therapy.

Clinical Trial Description

The study consists of up to three cemiplimab dose cohorts (n=10 participants each). The cohorts will open sequentially, based on the safety of the previous cohort. Cohort 1 will open first to examine the lowest dose. When Cohort 1 participants have completed study week 18 visit and there are no safety concerns, Cohort 2 will open for enrollment. A similar assessment will be conducted with Cohort 2 to make a decision on opening Cohort 3. In each cohort, participants enter the study 6 weeks prior to initiation of treatment. The 6-week lead-in period is followed by a 6-week treatment period where two infusions of cemiplimab are administered 6 weeks apart, at study weeks 6 and 12. The total study duration per participant is 90 weeks, including 78 weeks of follow-up after the treatment period. Study visit schedule includes visits at entry, and weeks 6, 7, 8, 10, 12, 13, 14, 16, 17, 18, 22, 24, 30, 36, 54, 72 and 90. Evaluations include: a medical and medication history; assessment of HBV antiviral therapy adherence; physical exam; blood, urine, and fecal collection; rectal swab; liver biopsy and fine needle aspiration; and optional leukapheresis. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04046107
Study type Interventional
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact
Status Withdrawn
Phase Phase 1/Phase 2
Start date January 1, 2024
Completion date September 30, 2027
View Details
See also
  Status Clinical Trial Phase
Completed NCT03459521 - Efficacy of HBVaxpro40© and Fendrix© in Patients With Chronic Liver Disease. N/A
Completed NCT02060162 - Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa
Completed NCT00912847 - Validity and Cost-Effectiveness of a New Screening Test for Hepatocellular Carcinoma N/A
Completed NCT04072211 - Demonstration Project on Health Care Worker Protection Against Hepatitis B in Kalulushi District Phase 4
Completed NCT01204762 - Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen Phase 2
Completed NCT00805675 - Effects of Telbivudine and Tenofovir Disoproxil Fumarate Treatment on the Hepatitis B Virus DNA Kinetics in CHB Phase 3
Completed NCT02785835 - Hepatocellular Carcinoma in HIV-infected Patients
Completed NCT03083821 - A Study to Provide a Better Understanding of Baraclude's Pharmacokinetic Properties in a Real World Clinical Setting Phase 1
Recruiting NCT01083251 - The Beneficial Effect of Vitamin D Supplement to Peg Interferon Alpha 2a or to Telbivudine Monotherapy in Patients With Chronic Hepatitis B Virus (HBV) Infection N/A
Not yet recruiting NCT05752890 - A Novel Biomarker for Response and Prognosis of HBV-related Hepatocellular Carcinoma
Recruiting NCT04231565 - Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA. N/A
Terminated NCT00678587 - Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures Phase 3
Completed NCT00739752 - Interventions to Increase HBV Vaccinations in Sexually Transmitted Disease (STD) Clinics N/A
Completed NCT03294798 - Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitis B Patient Phase 1/Phase 2
Withdrawn NCT04385524 - Use of Dynavax Heplisav B in Healthcare Workers Previously Vaccinated With 3-dose Vaccine Who Failed to Demonstrate Seroprotection N/A
Enrolling by invitation NCT00663182 - Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis Phase 4
Completed NCT00769730 - Evaluation the Possible Influence of Transcatheter Arterial Chemoembolization on Hepatitis B Viral Replication N/A
Completed NCT01438424 - Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials Phase 2
Completed NCT05406089 - Effects of Antiviral Therapy on Patients With HBV-related HCC
Completed NCT03625258 - Mutations of the Pre-core Region of Hepatite B Virus (HBV)